Rhythm Pharmaceuticals (RYTM) Competitors $63.44 +0.42 (+0.66%) As of 01:22 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock RYTM vs. ITCI, GMAB, SMMT, RDY, ASND, MRNA, VTRS, QGEN, BPMC, and ROIVShould you be buying Rhythm Pharmaceuticals stock or one of its competitors? The main competitors of Rhythm Pharmaceuticals include Intra-Cellular Therapies (ITCI), Genmab A/S (GMAB), Summit Therapeutics (SMMT), Dr. Reddy's Laboratories (RDY), Ascendis Pharma A/S (ASND), Moderna (MRNA), Viatris (VTRS), Qiagen (QGEN), Blueprint Medicines (BPMC), and Roivant Sciences (ROIV). These companies are all part of the "pharmaceutical products" industry. Rhythm Pharmaceuticals vs. Its Competitors Intra-Cellular Therapies Genmab A/S Summit Therapeutics Dr. Reddy's Laboratories Ascendis Pharma A/S Moderna Viatris Qiagen Blueprint Medicines Roivant Sciences Rhythm Pharmaceuticals (NASDAQ:RYTM) and Intra-Cellular Therapies (NASDAQ:ITCI) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, community ranking, dividends, risk, media sentiment, valuation, earnings, profitability and institutional ownership. Do institutionals and insiders believe in RYTM or ITCI? 92.3% of Intra-Cellular Therapies shares are owned by institutional investors. 6.1% of Rhythm Pharmaceuticals shares are owned by company insiders. Comparatively, 2.6% of Intra-Cellular Therapies shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Which has more volatility and risk, RYTM or ITCI? Rhythm Pharmaceuticals has a beta of 2.3, indicating that its share price is 130% more volatile than the S&P 500. Comparatively, Intra-Cellular Therapies has a beta of 0.69, indicating that its share price is 31% less volatile than the S&P 500. Do analysts prefer RYTM or ITCI? Rhythm Pharmaceuticals currently has a consensus price target of $76.62, suggesting a potential upside of 20.78%. Intra-Cellular Therapies has a consensus price target of $109.70, suggesting a potential downside of 16.81%. Given Rhythm Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts clearly believe Rhythm Pharmaceuticals is more favorable than Intra-Cellular Therapies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Rhythm Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 13 Buy rating(s) 0 Strong Buy rating(s) 3.00Intra-Cellular Therapies 0 Sell rating(s) 10 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.17 Does the MarketBeat Community prefer RYTM or ITCI? Intra-Cellular Therapies received 211 more outperform votes than Rhythm Pharmaceuticals when rated by MarketBeat users. However, 68.20% of users gave Rhythm Pharmaceuticals an outperform vote while only 65.74% of users gave Intra-Cellular Therapies an outperform vote. CompanyUnderperformOutperformRhythm PharmaceuticalsOutperform Votes31168.20% Underperform Votes14531.80% Intra-Cellular TherapiesOutperform Votes52265.74% Underperform Votes27234.26% Does the media prefer RYTM or ITCI? In the previous week, Rhythm Pharmaceuticals had 12 more articles in the media than Intra-Cellular Therapies. MarketBeat recorded 12 mentions for Rhythm Pharmaceuticals and 0 mentions for Intra-Cellular Therapies. Rhythm Pharmaceuticals' average media sentiment score of 0.56 beat Intra-Cellular Therapies' score of 0.00 indicating that Rhythm Pharmaceuticals is being referred to more favorably in the media. Company Overall Sentiment Rhythm Pharmaceuticals Positive Intra-Cellular Therapies Neutral Is RYTM or ITCI more profitable? Intra-Cellular Therapies has a net margin of -14.07% compared to Rhythm Pharmaceuticals' net margin of -230.07%. Intra-Cellular Therapies' return on equity of -9.93% beat Rhythm Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Rhythm Pharmaceuticals-230.07% -367.36% -77.47% Intra-Cellular Therapies -14.07%-9.93%-8.38% Which has better earnings and valuation, RYTM or ITCI? Intra-Cellular Therapies has higher revenue and earnings than Rhythm Pharmaceuticals. Intra-Cellular Therapies is trading at a lower price-to-earnings ratio than Rhythm Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRhythm Pharmaceuticals$136.86M29.49-$184.68M-$2.81-22.57Intra-Cellular Therapies$680.50M20.64-$139.67M-$0.73-180.64 SummaryRhythm Pharmaceuticals beats Intra-Cellular Therapies on 10 of the 18 factors compared between the two stocks. Get Rhythm Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for RYTM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RYTM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RYTM vs. The Competition Export to ExcelMetricRhythm PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.04B$6.92B$5.61B$8.57BDividend YieldN/A2.54%5.28%4.17%P/E Ratio-14.658.6327.2219.81Price / Sales29.49265.57411.31154.51Price / CashN/A65.8538.3234.64Price / Book22.106.587.014.65Net Income-$184.68M$143.75M$3.23B$248.05M7 Day Performance-6.86%1.52%-0.06%-0.15%1 Month Performance11.70%12.43%8.75%4.50%1 Year Performance42.97%3.67%32.44%13.76% Rhythm Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RYTMRhythm Pharmaceuticals4.1729 of 5 stars$63.44+0.7%$76.62+20.8%+49.1%$4.04B$136.86M-14.65140Insider TradeITCIIntra-Cellular Therapies0.8986 of 5 stars$131.87flat$109.70-16.8%N/A$14.05B$680.50M-151.57560GMABGenmab A/S3.8638 of 5 stars$21.77+3.9%$39.17+79.9%-13.7%$13.96B$3.12B12.511,660Positive NewsGap UpSMMTSummit Therapeutics2.9081 of 5 stars$17.73-2.7%$37.40+110.9%+144.4%$13.17B$700K-63.32110Analyst UpgradeAnalyst RevisionGap DownHigh Trading VolumeRDYDr. Reddy's Laboratories1.3324 of 5 stars$14.73+0.0%$17.00+15.4%+12.6%$12.29B$325.54B23.4524,800ASNDAscendis Pharma A/S3.4192 of 5 stars$175.69+7.9%$216.07+23.0%+30.2%$10.71B$368.70M-24.75640Analyst ForecastAnalyst RevisionMRNAModerna4.4613 of 5 stars$27.05+1.8%$53.58+98.1%-81.5%$10.46B$3.14B-2.913,900Gap DownVTRSViatris2.5478 of 5 stars$8.69-1.1%$10.50+20.8%-14.5%$10.20B$14.33B-11.7437,000QGENQiagen3.3686 of 5 stars$44.89-0.5%$48.42+7.9%+10.2%$9.98B$2.00B125.006,030Positive NewsBPMCBlueprint Medicines1.1757 of 5 stars$127.79+26.1%$125.69-1.6%+20.8%$8.25B$562.12M-118.32640High Trading VolumeROIVRoivant Sciences2.3766 of 5 stars$11.17+1.6%$17.50+56.7%+5.9%$7.97B$29.05M-74.46860 Related Companies and Tools Related Companies Intra-Cellular Therapies Competitors Genmab A/S Competitors Summit Therapeutics Competitors Dr. Reddy's Laboratories Competitors Ascendis Pharma A/S Competitors Moderna Competitors Viatris Competitors Qiagen Competitors Blueprint Medicines Competitors Roivant Sciences Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RYTM) was last updated on 6/13/2025 by MarketBeat.com Staff From Our PartnersYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredWhy July 22nd Could Mean Big Changes for Social SecurityIn a stunning move, President Trump has authorized an AI-led transformation of federal agencies, including Soc...Altimetry | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredBanks aren’t ready for this altcoin—are you?Donald Trump just fast-tracked TWO major crypto bills with an August deadline! Your window of opportunity i...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rhythm Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Rhythm Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy RYTM Stock Free RYTM Stock Alerts